Effect of curcumin on lipid profile, fibrosis, and apoptosis in liver tissue in abemaciclib-administered rats.
Sign Up to like & getrecommendations! Published in 2022 at "Drug and chemical toxicology"
DOI: 10.1080/01480545.2022.2135007
Abstract: Abemaciclib (ABEM) is an important antitumor agent for breast cancer treatment. However, the side-effects of ABEM are unclear in the liver. This study investigated the protective effect of curcumin (CURC) on liver damage caused by… read more here.
Keywords: liver; group; effect curcumin; abemaciclib ... See more keywords
Development and Validation of a Quantitative LC-MS/MS Method for CDK4/6 Inhibitors Palbociclib, Ribociclib, Abemaciclib, and Abemaciclib-M2 in Human Plasma
Sign Up to like & getrecommendations! Published in 2023 at "Therapeutic Drug Monitoring"
DOI: 10.1097/ftd.0000000000001063
Abstract: Supplemental Digital Content is Available in the Text. Background: The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, palbociclib, ribociclib, and abemaciclib, are standard-of-care agents for patients with hormone receptor–positive human epidermal growth factor receptor 2–negative… read more here.
Keywords: drug; human plasma; cdk4 inhibitors; abemaciclib ... See more keywords
Abemaciclib drives the therapeutic differentiation of acute myeloid leukaemia stem cells
Sign Up to like & getrecommendations! Published in 2023 at "British Journal of Haematology"
DOI: 10.1111/bjh.18735
Abstract: Self‐renewal and differentiation arrest are two features of leukaemia stem cells (LSCs) responsible for the high relapse rate of acute myeloid leukaemia (AML). To screen drugs to overcome differentiation blockade for AML, we conducted screening… read more here.
Keywords: myeloid; leukaemia stem; abemaciclib; differentiation ... See more keywords
Abstract CT159: CYCLONE 1: abemaciclib in men with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct159
Abstract: Background: Treatment options for patients (pts) with heavily pretreated mCRPC are limited. Augmenting endocrine therapy by targeting CDK4/6 with abemaciclib has dramatically improved outcomes in HR+ breast cancer. Similar to ER, AR signaling activates CDK4… read more here.
Keywords: prostate cancer; heavily pretreated; abemaciclib; mcrpc ... See more keywords
Abstract B43: The CDK4 and 6 inhibitor abemaciclib induces both epigenetic and immunogenic responses in preclinical models of Ewing’s sarcoma
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.pedca17-b43
Abstract: Ewing’s sarcoma (ES) is a rare but aggressive cancer typically occurring in the bone or soft tissue of children and adolescents. Current treatment regimens composed of surgery, radiation, and high-dose chemotherapy have improved outcomes for… read more here.
Keywords: epigenetic immunogenic; preclinical models; cancer; cell ... See more keywords
Abstract P5-14-05: The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs19-p5-14-05
Abstract: Background: Abemaciclib is an orally administered inhibitor of cyclin-dependent kinase (CDK) 4/6, dosed twice daily (BID) on a continuous schedule. Diarrhea is a frequently associated adverse event. It is predictable and manageable with antidiarrheal medication,… read more here.
Keywords: treatment; study; breast cancer; cancer ... See more keywords
Abstract PS5-10:Esr1mutation as a potential predictor of abemaciclib benefit following prior cdk4/6 inhibitor (cdk4/6i) progression in hormone receptor-positive (hr+) metastatic breast cancer (mbc): A translational investigation
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs20-ps5-10
Abstract: Background: CDK4/6 inhibitors have emerged as the standard of care for HR+ MBC. However, there is limited insight into the potential benefit of abemaciclib following prior progression on palbociclib or ribociclib. Based on a multi-center… read more here.
Keywords: following prior; progression palbociclib; progression; cancer ... See more keywords
Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison
Sign Up to like & getrecommendations! Published in 2023 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359231152843
Abstract: Background: A cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + endocrine therapy is recommended as first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC). Quality of life (QoL) is an important endpoint that… read more here.
Keywords: first line; breast cancer; abemaciclib; treatment ... See more keywords
Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood-2022-158678
Abstract: Introduction: Patients (pts) with primary and secondary myelofibrosis (MF) have a reduced life expectancy. While several oral Janus Kinase (JAK)-1/2 inhibitors such as ruxolitinib (RUX) have demonstrated improvements in symptom burden and spleen volume reduction… read more here.
Keywords: combination; rux; abemaciclib; phase ... See more keywords
Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.829759
Abstract: Abemaciclib is a cyclin-dependent kinases 4/6 (CDK4/6) inhibitor approved for the treatment of metastatic breast cancer. Preclinical studies suggest that abemaciclib has the potential for lung cancer treatment. However, several clinical trials demonstrate that monotherapy… read more here.
Keywords: lung cancer; cancer; abemaciclib; treatment ... See more keywords